Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials

@article{Qiu2015EffectivenessAS,
  title={Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials},
  author={Sangsang Qiu and Ye Shen and Hongqiu Pan and Jianming Wang and Qun Zhang},
  journal={Infectious Diseases},
  year={2015},
  volume={47},
  pages={808 - 819}
}
Abstract Background: Oseltamivir has been widely used to treat patients with influenza; however, its effects have been debated. Recently, a new meta-analysis on the controversial topic of oseltamivir’s effectiveness found that the drug reduces the duration of influenza symptoms and the risk of hospitalization, while increasing the risk of nausea and vomiting. Unfortunately, the analysis did not include articles published in Chinese. Thus, we performed an updated meta-analysis by adding more… Expand
Use of Oseltamivir in Lung Transplant Recipients with Suspected or Proven Influenza Infection: A 1-Year Observational Study of Outcomes and Safety
TLDR
This non-controlled retrospective analysis suggests that the preemptive use of oseltamivir for respiratory tract infections pending microbiological results is safe in LTRs. Expand
Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques
TLDR
Oseltamivir treatment at 2 different doses reduced A(H7N9) viral titers in infected animals, but even high-dose oseltAMivir did not block viral replication sufficiently to suppress the emergence of resistant variants. Expand
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
  • T. Uyeki, H. Bernstein, +15 authors A. Pavia
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
TLDR
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America in 2009 and address new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. Expand
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
  • T. Uyeki, H. Bernstein, +15 authors A. Pavia
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
TLDR
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America in 2009 and address new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. Expand
Antiviral Treatment of Flu: Is a Vicious Circle?
TLDR
With elimination of the pathogen by antiviral drugs, it may eliminate the need to improve the immune response of the host and it may be eventuate to continuing epidemics of influenza. Expand
Update on Prevention Efforts for Pneumonia Attributed Deaths in Children Under 5 Years of Age
TLDR
Effective strategies such as early detection of signs of danger, access to appropriate care in a timely manner, appropriate antibiotics administered early on, the use of Kangaroo mother care, supplementation of zinc, vaccination and community interventions must to be considered in order to reduce the burden of childhood mortality due to respiratory diseases. Expand
Controlling Bacterial Super-infection During Influenza
TLDR
WLBU2 may be effective for bacterial pneumonia alone, but IFNλ should not be used as a treatment for influenza due to the high risk of mortality and morbidity from bacterial super-infection. Expand
Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study
TLDR
This retrospective cohort study aimed to evaluate whether time to influenza diagnosis in patients with severe influenza is associated with the duration of antibiotic therapy. Expand
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
Timothy M. Uyeki, Henry H. Bernstein, John S. Bradley, Janet A. Englund, Thomas M. File Jr, Alicia M. Fry, Stefan Gravenstein, Frederick G. Hayden, Scott A. Harper, Jon Mark Hirshon, Michael G. Ison,Expand
Academic Life in Emergency Medicine (ALiEM) Blog and Podcast Watch: Infectious Diseases
TLDR
This review summarizes the accredited posts on infectious diseases meeting the authors' a priori quality criteria per evaluation by the reviewers. Expand
...
1
2
...

References

SHOWING 1-10 OF 111 REFERENCES
Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials.
TLDR
There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population. Expand
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials
TLDR
The findings show that oseltamivir in adults with influenza accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital, but increases the occurrence of nausea and vomiting. Expand
[A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients].
TLDR
Oseltamivir is effective and well tolerated in suspected influenza patients, it can reduces the duration and severity of influenza symptom and fever, decrease the incidence of suspected influenza in the contacted population, antibiotic using, and with light side-effect. Expand
Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza
  • M. Ebell
  • Medicine
  • Evidence-Based Medicine
  • 2014
TLDR
A systematic review of the published and unpublished data of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children concluded that oseltamivir reduced the likelihood of complications requiring an antibiotic. Expand
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
TLDR
Oseltamivir was effective and well tolerated in the treatment of natural influenza infection in adults and was associated with higher symptom scores, less viral shedding, and improved health, activity, and sleep quality. Expand
A study on the efficacy and safety of Oseltamivir in the treatment of suspected influenza patients
TLDR
The data suggests that Oseltamivir is effective and well tolerated in suspected influenza patients and can reduces the duration and severity of influenza symptom with mid side effect. Expand
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
TLDR
Oseltamivir was associated with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep quality, and was well tolerated in the treatment of natural influenza infection in adults. Expand
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
TLDR
The effect on unverified pneumonia in children and for prophylaxis was not significant and there was no significant reduction in risk of unverified bronchitis, otitis media, sinusitis, or any complication classified as serious or that led to study withdrawal. Expand
A Randomized and Controlled Clinical Evaluation of Oseltamivir in the Treatment of Influenza
TLDR
Oseltamivir is effective and well tolerated in the treatment of influenza and decreases the usage rate of antibiotics and the temporary infusion. Expand
Influenza: the rational use of oseltamivir
TLDR
Oseltamivir treatment with 75 mg twice a day for 5 days resulted in a signifi cant 21% (95% CI 15–26) reduction, from 123 h to 98 h, in reported symptom duration in adult and adolescent patients with laboratory-confi rmed infl uenza group. Expand
...
1
2
3
4
5
...